Abivax Shares Drop 2.5% but Still Up 1,240% Over the Year

A Decline That Does Not Undermine the Medium-Term Upward Trend

Abivax shares fell by 2.2% to €115.50, down from €118.10 the previous day. The stock is among the largest declines in the SBF 120, while the broad index gained 0.29%. However, the movement remains anecdotal in light of the stock's performance: it shows +35.8% over a month and +1,240% over a year.

The price remains above its three moving averages, with a gap of +13.47% compared to the MM50 (€101.79) and +15.86% against the MM200 (€99.69). The RSI at 58 remains in the neutral zone, with no signs of exhaustion at this stage. The ongoing consolidation follows the early July completion of a $920 million Wall Street fundraising, securing the group's financing until 2029.

Bearish Bets Significantly Retreat on the Capital

According to reviewed statements, four funds hold a net short position of 4.78% of the capital, down by 1.33 points over thirty days (from 6.11% a month ago). This movement reflects a reduction in bearish bets, even though the overall level remains high and signals continued caution from institutional investors positioned against the stock. The easing follows the positive clinical results of part 2 of the ABTECT trial on obefazimod, unveiled on June 30, which triggered the stock's surge.

During the announcement on June 29, 2026, the company indicated it was preparing to file its marketing authorization application in the United States within the year. The American listing in the form of ADS on Nasdaq, now the most liquid venue for the stock with a volume about four times that of Paris, remains synchronized with Euronext.